

Reference number(s)
1966-A

SPECIALTY GUIDELINE MANAGEMENT

ELIGARD (leuprolide acetate)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Palliative treatment of advanced prostate cancer

B. Compendial Uses

1. Prostate cancer
2. Recurrent androgen receptor positive salivary gland tumors
3. Gender Dysphoria (also known as gender non-conforming or transgender persons)

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

A. **Prostate cancer**

Authorization of 12 months may be granted for treatment of prostate cancer.

B. **Gender dysphoria**

1. Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member when all of the following criteria are met:
 - a. The member has a diagnosis of gender dysphoria.
 - b. The member has reached Tanner stage 2 of puberty or greater.
2. Authorization of 12 months may be granted for gender transition when all of the following criteria are met:
 - a. The member has a diagnosis of gender dysphoria.
 - b. The member will receive Eligard concomitantly with gender-affirming hormones.

C. **Salivary gland tumors**

Authorization of 12 months may be granted for treatment of recurrent salivary gland tumors when the tumor is androgen receptor positive.

III. CONTINUATION OF THERAPY

- A. Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy and who have not experienced an unacceptable toxicity for the specified indications below:
1. Prostate cancer

Reference number(s)
1966-A

2. Salivary gland tumors

- B. All members (including new members) requesting authorization for continuation of therapy for gender dysphoria must meet all initial authorization criteria.

IV. REFERENCES

1. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals; September 2019.
2. The NCCN Drugs & Biologics Compendium® © 2020 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 12, 2020.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 4.2019. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed February 11, 2020.
4. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869–3903.
5. Gender Identity Research and Education Society. Guidance for GPs and other clinicians on the treatment of gender variant people. UK Department of Health. Published March 10, 2008.
6. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, 7th version. ©2012 World Professional Association for Transgender Health. Available at <http://www.wpath.org>.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck tumors. Version 1.2020. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed February 12, 2020.